JP2002511431A - 異種反応性抗体の阻害 - Google Patents

異種反応性抗体の阻害

Info

Publication number
JP2002511431A
JP2002511431A JP2000543171A JP2000543171A JP2002511431A JP 2002511431 A JP2002511431 A JP 2002511431A JP 2000543171 A JP2000543171 A JP 2000543171A JP 2000543171 A JP2000543171 A JP 2000543171A JP 2002511431 A JP2002511431 A JP 2002511431A
Authority
JP
Japan
Prior art keywords
polymer
αgal
gal
antibody
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002511431A5 (https=
Inventor
アレキサンダー シュワルツ，
トーマス エイ． デイビス，
リサ イー． ダイアモンド，
ジョン エス． ローガン，
ゲラルド ダブリュー． バイルン，
Original Assignee
バクスター インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスター インターナショナル インコーポレイテッド filed Critical バクスター インターナショナル インコーポレイテッド
Publication of JP2002511431A publication Critical patent/JP2002511431A/ja
Publication of JP2002511431A5 publication Critical patent/JP2002511431A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000543171A 1998-04-15 1999-04-15 異種反応性抗体の阻害 Pending JP2002511431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6052598A 1998-04-15 1998-04-15
US09/060,525 1998-04-15
PCT/US1999/008326 WO1999052561A1 (en) 1998-04-15 1999-04-15 Inhibition of xenoreactive antibodies

Publications (2)

Publication Number Publication Date
JP2002511431A true JP2002511431A (ja) 2002-04-16
JP2002511431A5 JP2002511431A5 (https=) 2006-06-08

Family

ID=22030043

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543171A Pending JP2002511431A (ja) 1998-04-15 1999-04-15 異種反応性抗体の阻害

Country Status (9)

Country Link
US (3) US6572867B1 (https=)
EP (1) EP1087791B1 (https=)
JP (1) JP2002511431A (https=)
AT (1) ATE304865T1 (https=)
AU (1) AU761831B2 (https=)
CA (1) CA2326618A1 (https=)
DE (2) DE69927369T2 (https=)
ES (1) ES2249890T3 (https=)
WO (1) WO1999052561A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523936A (ja) * 2008-02-27 2011-08-25 レツク・フアーマシユーテイカルズ・デー・デー セレン含有改質剤及びコンジュゲート（Ｃｏｎｊｕｇａｔｅｓ）
JP2017525763A (ja) * 2014-08-22 2017-09-07 インスティトゥート ディンベスティガシオ ビオメディカ デ ベルビッチェ（イディベル） 感染症の予防および／または治療のための方法および試薬

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
JP2002531531A (ja) * 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
EP1257558A1 (en) * 2000-01-13 2002-11-20 Alchemia Pty Ltd Methods for synthesis of alpha-d-gal (1- 3) gal-containing oligosaccharides
US7270961B2 (en) * 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
US20060099169A1 (en) * 2004-10-13 2006-05-11 Ilypsa, Inc. Toxin binding compositions
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011139488A2 (en) 2010-05-06 2011-11-10 Mayo Foundation For Medical Education And Research Methods and materials for reducing cardiac xenograft rejection
US20130149331A1 (en) * 2011-05-03 2013-06-13 Peng George Wang Rhamnose and forssman conjugated immunogenic agents
US9533214B2 (en) 2012-09-25 2017-01-03 Igt Gaming system and method for providing plays of multiple games
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
CA2965550A1 (en) 2014-10-22 2016-04-28 Indiana University Research & Technology Corporation Triple transgenic pigs suitable for xenograft
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
WO2021234676A1 (en) 2020-05-22 2021-11-25 Aab Therapeutics, Llc Compounds and methods for suppressing an immune response to substances containing polyethylene glycol

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8001748L (sv) * 1980-03-05 1981-09-06 Kaellenius Gunilla Kompositioner for terapeutisk eller diagnostisk anvendning jemte forfarande for terapeutik
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
WO1993003735A1 (en) * 1991-08-23 1993-03-04 Alberta Research Council Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
AU2158995A (en) * 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
AU1404597A (en) * 1995-12-21 1997-07-17 Procur Ab Galactopyranosides and their use
WO1998033528A2 (en) * 1997-02-05 1998-08-06 Biotransplant, Inc. Induction of b cell tolerance
US6676946B2 (en) * 1997-03-27 2004-01-13 Institut Pasteur Multiple antigen glycopeptide carbohydrate vaccine comprising the same and use thereof
PT970114E (pt) * 1997-04-18 2006-12-29 Novartis Ag Neoglicoproteínas
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523936A (ja) * 2008-02-27 2011-08-25 レツク・フアーマシユーテイカルズ・デー・デー セレン含有改質剤及びコンジュゲート（Ｃｏｎｊｕｇａｔｅｓ）
JP2017525763A (ja) * 2014-08-22 2017-09-07 インスティトゥート ディンベスティガシオ ビオメディカ デ ベルビッチェ（イディベル） 感染症の予防および／または治療のための方法および試薬

Also Published As

Publication number Publication date
ATE304865T1 (de) 2005-10-15
WO1999052561A1 (en) 1999-10-21
EP1087791B1 (en) 2005-09-21
ES2249890T3 (es) 2006-04-01
EP1087791A1 (en) 2001-04-04
US20040141944A1 (en) 2004-07-22
CA2326618A1 (en) 1999-10-21
HK1036223A1 (en) 2001-12-28
DE1087791T1 (de) 2002-02-21
AU3564599A (en) 1999-11-01
DE69927369D1 (de) 2006-02-02
DE69927369T2 (de) 2006-06-22
US6572867B1 (en) 2003-06-03
US20080124396A1 (en) 2008-05-29
AU761831B2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
US20080124396A1 (en) Inhibition of Xenoreactive Antibodies
Lin et al. Recipient tissue factor expression is associated with consumptive coagulopathy in pig‐to‐primate kidney xenotransplantation
US6495332B2 (en) Methods and compositions for ameliorating the symptoms of sepsis
US5679345A (en) Method for preventing complement-dependent rejection of organ or tissue transplants
US6399578B1 (en) Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
WO2015023972A1 (en) Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
OSORIO et al. PROLONGATION OF IN VIVO MOUSE ISLET ALLOGRAFT SURVIVAL BY MODULATION OF MHC CLASS I ANTIGENs
WO1996008272A1 (en) Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
Wu et al. GENETIC CONTROL OF THE HUMORAL IMMUNE RESPONSE TO XENOGRAFTS: I. Functional Characterization of Rat Monoclonal Antibodies to Hamster Heart Xenografts: 1
Bach et al. Xenotransplantation: a current perspective
JP2001518074A (ja) Ｂ細胞の免疫寛容誘導
HK1036223B (en) Inhibition of xenoreactive antibodies
US20030017152A1 (en) Non-lethal methods for conditioning a recipient for bone marrow transplantation
JP2012530106A (ja) ＨＬＡ−Ｇα１多量体及びその薬学的使用
EP4051298A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progentor cells
Khedraki C1Q Production by Resident Versus Infiltrating LY6C+ Cells in MHC Mismatched Murine Kidney Transplants
Pincus et al. Evaluation of antigen-based heteropolymer for treatment of systemic lupus erythematosus in a nonhuman primate model
Alsughayyir Humoral alloimmunity in cardiac allograft rejection
KR20240160596A (ko) Peg-인지질 분자의 새로운 용도
AU703169C (en) Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
Pruitt The role of antibody and complement in hyperacute xenograft rejection
Price The effects of polymer-mediated immunocamouflage on allorecognition of blood cells
Singh Immunoadsorption for the prolongation of ex vivo cardiac xenograft survival
Coulombe et al. 6 THE IMMUNOBIOLOGY OF PANCREATIC ISLET TRANSPLANTATION
Lowe Characterisation of HLA-specific antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100510